The efficacy of talquetamab depended on the expression level of GPRC5D and the effector-to-target (E:T) ratio, where high expression level of GPRC5D and a high E:T ratio were associated with improved lysis of MM cells. Here, GPRC5D is linked to Miyoshi myopathy.